{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-044204","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.215573+00:00","generated_at":"2026-06-19T05:08:46.634020+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NICE recommends Vir's sotrovimab for COVID-19 in UK; no meaningful 2023 sales expected","bullets":["NICE final draft guidance recommends sotrovimab for high-risk adults where Paxlovid is contraindicated or unsuitable.","Recommendation based on cost-effectiveness evaluation of sotrovimab.","No meaningful additional UK sales of sotrovimab anticipated in 2023 due to existing inventory.","Sotrovimab (Xevudy) authorized in over 40 countries; not authorized in the US."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-044204","json":"https://secwatch.observer/filing/0001193125-23-044204.json","markdown":"https://secwatch.observer/filing/0001193125-23-044204.md","text":"https://secwatch.observer/filing/0001193125-23-044204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000119312523044204/0001193125-23-044204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000119312523044204/d444727d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T05:08:46.634020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}